| Budget Amount *help |
¥188,500,000 (Direct Cost: ¥145,000,000、Indirect Cost: ¥43,500,000)
Fiscal Year 2014: ¥36,140,000 (Direct Cost: ¥27,800,000、Indirect Cost: ¥8,340,000)
Fiscal Year 2013: ¥37,830,000 (Direct Cost: ¥29,100,000、Indirect Cost: ¥8,730,000)
Fiscal Year 2012: ¥39,650,000 (Direct Cost: ¥30,500,000、Indirect Cost: ¥9,150,000)
Fiscal Year 2011: ¥39,260,000 (Direct Cost: ¥30,200,000、Indirect Cost: ¥9,060,000)
Fiscal Year 2010: ¥35,620,000 (Direct Cost: ¥27,400,000、Indirect Cost: ¥8,220,000)
|
|---|
| Outline of Final Research Achievements |
In order to examine the generality of translesion synthesis (TLS), which coordinates replication and repair, we analyzed the structure of co-crystals of human DNA polymerase eta (Pol eta) and CPD-containing DNA with X-ray diffraction. We found that human Pol eta acts like a molecular splint to stabilize damaged DNA in a normal B-form conformation. On the other hand, the crystal structure of human Pol eta and cisplatin-containing DNA revealed that Pol eta could not act like a molecular splint. Mono- or polyubiquitination of PCNA controls the pathway choice of DNA damage tolerance. We demonstrated that PCNA is poly-ubiquitinated via transfer of a pre-formed ubiquitin chain on monoubiquitinated PCNA.
|
